ACET adicetbio.com: מקדם חוב לטווח ארוך להון

Adicet Bio revenues rely on settlements with insurance funds and lymphoma treatment clinics. Drug production is organized through certified CDMO partners in California. The development strategy excludes mergers, focusing instead on seeking co-investors for clinical trials. Long-term debt-to-equity reflects credit risk dynamics, while 0.08 is recorded as the baseline value for the current financial burden.

The metric is calculated as the ratio of total liabilities with a maturity exceeding one year to total equity. It determines the extent of the company's dependence on external long-term financing relative to its net assets. For Adicet Bio (ACET), such borrowings are critical when upgrading bioreactors to meet ESG environmental standards. Analyzing the current long-term debt-to-equity trend allows for an assessment of the financing structure's stability.